Summary.-The influence of anaesthetics on the in vivo response of B16 melanoma to melphalan was studied using an in vitro cell-survival assay. Three anaesthetics were used, Saffan (Althesin) Sagatal (Nembutal) and Hypnorm. When Saffan was administered to tumour-bearing animals before melphalan there was a significant increase in tumour-cell kill. This effect was not observed with Sagatal or Hypnorm.
ANAESTHETICS are widely used in radiobiological studies on small animals, and sometimes in studies with cytotoxic drugs. However, it is becoming apparent that the use of anaesthetics for convenience is inadvisable, since they can produce major changes in blood pressure, tumour blood flow and body temperature (Johnson et al., 1976) and can influence the response of normal and tumour tissue to cytotoxic treatments (Bruce et al., 1970; Kaizer & Van Putten, 1973; Garattini et al., 1974; Fu & Phillips, 1976) . In this paper we describe the influence of several anaesthetics on the survival of B16 melanoma tumour cells to in vivo treatments with melphalan.
MATERIALS ANI) AIETHODS
Mice and tumnours.-Female C57BL mice were obtained from the Institute of Cancer Research breeding centre. They were used when 8-10 weeks old, and weighed 18-25 g. Drugs.-L-phenylalanine mustard (melphalan) was obtained from Burroughs Wellcome Ltd, Beckenham, Kent, in 100 mg vials. It was dissolved in acid-ethanol (1 ml) and the volume was made up to 10 ml with buffered diluent (both supplied by the manufacturers). For further dilutions PBS-"A" (Dulbecco & Vogt, 1954) was used.
Preparation of cell suspensions.-Cell suspensions were prepared as described previously . The mean cell yield per gram of tissue trypsinized for untreated tumours was 9-9 x 107 (s.d. 2-5 x 107, n = 23). Vital staining with trypan blue indicated viability > 95%.
In vitro cell-survival assays.-Survival of B16 melanoma cells was measured using the soft-agar assay first described by Courtenay (1976) and modified by In vitro drug treatment.-Cell suspensions of untreated tumours were prepared as described above, and the cells suspended in Ham's F12 culture medium. Drugs were added to the suspensions, and after 1 h of exposure the suspensions were centrifuged, the pellet washed and resuspended in fresh medium. Cell survival was measured in the soft-agar assay.
RESULTS

Influence of anaesthetics on melphalan dose-survival curve
The dose-response curve of B16 melanoma to melphalan in conscious animals is shown in Fig. 1 
Timing of Saffan administration
Saffan (90 mg/kg) was administered at various times from 6 h before to 2 h after melphalan (7.5 mg/kg) and the results are shown in Fig. 4 . In conscious animals this dose reduced survival to 10% of the control. Maximum enhancement of melphalan cytotoxicity was achieved when Saffan was administered shortly before melphalan. Anaesthesia at this time approximately doubled the log kill of tumour cells due to melphalan alone.
When Saffan was given earlier, the degree of enhancement gradually fell and by 6 h no significant enhancement was apparent. Since animals only remained After 15 mg/kg of melphalan, also in unanaesthetized mice (Fig. 6b) , there was a greater reduction in the tumour growth (TD= 5 days) than at the lower dose. population began immediately with a TD of 0O8 days, until between Days 7 and 8, when the rate slowed to a TD of about 5 days, corresponding with that of the tumour weight and total cells per tumour. When the lower dose of melphalan (7.5 mg/kg) was given to animals treated 20 min earlier with Saffan at 90 mg/kg (Fig. 6c) , the initial cell kill and the pattern of repopulation were similar to those observed with the higher dose of melphalan alone (15 mg/kg).
Influence of Saffan on melphalan dosesurvival curve in vitro B 16 melanoma cells were exposed in vitro to various doses of melphalan from 0 5 to 5 ,ug/ml (Fig. 7) . Melphalan at 5 ,ug/ml produced 3 decades of cell kill. The repopulation studies were performed to establish whether the enhanced cell kill achieved with melphalan + Saffan also led to enhanced growth delay, but they also allow a comparison of the repopulation after melphalan, with the repopulation patterns reported previously in the B16 melanoma for cyclophospha-\ mide and CCNU Wilkinson & Harrap (1978) iat there have found increased antitumour effect ration of when melphalan and prednisolone were pretreat-combined. However, they also showed nents of increased host toxicity due to the comto con-bination, and with melphalan + Saffan, )tency of Dr M. Y. Gordon (personal communicasuggests tion) has shown enhanced cell kill in mouse ignificant marrow cells (ADC-Cs) similar to that probably observed in B16 melanoma. Lelphalan The results show clearly that Saffan is more anaesthesia markedly alters the response Lelphalan of both tumour and normal tissue to at observed least one cytotoxic treatment. Together may be with the work of others referred to above, inactive our results stress the importance of rate of including appropriate controls in all mnd. Re-experiments, and reinforce the current ely to be trend of avoiding anaesthetics whenever ;ained at possible. We would like to thank Dr G. G. Steel for his support throughout this work and during the preparation of the manuscript.
